Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)
6,020.00
-60.00 (-0.99%)
At close: Mar 27, 2026
Sinil Pharmaceutical Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 9,313 | 4,643 | 7,519 | 4,944 | 7,340 |
Short-Term Investments | 29,900 | 29,070 | 15,900 | 18,410 | 13,530 |
Cash & Short-Term Investments | 39,214 | 33,713 | 23,419 | 23,354 | 20,870 |
Cash Growth | 16.31% | 43.96% | 0.28% | 11.90% | 43.01% |
Accounts Receivable | 19,551 | 20,248 | 21,878 | 23,420 | 20,588 |
Other Receivables | 721.11 | 590.8 | 967.33 | 293.28 | 133.52 |
Receivables | 20,272 | 20,839 | 22,845 | 23,713 | 20,721 |
Inventory | 23,009 | 22,861 | 22,492 | 20,188 | 16,700 |
Prepaid Expenses | 27.71 | 28.18 | 27.45 | 19.92 | 24.67 |
Other Current Assets | 32.55 | 7.52 | 3.85 | 6.05 | 110.3 |
Total Current Assets | 82,555 | 77,449 | 68,787 | 67,280 | 58,427 |
Property, Plant & Equipment | 42,645 | 44,789 | 41,916 | 35,744 | 30,999 |
Long-Term Investments | 882.43 | 726.62 | 839.01 | 966.42 | 1,512 |
Other Intangible Assets | 2,382 | 1,736 | 1,810 | 1,870 | 1,801 |
Long-Term Accounts Receivable | 0 | - | - | - | - |
Long-Term Deferred Tax Assets | 2,569 | 2,413 | 2,097 | 1,944 | 1,804 |
Other Long-Term Assets | 38,455 | 38,698 | 36,960 | 34,978 | 34,381 |
Total Assets | 169,489 | 165,861 | 152,460 | 142,832 | 128,974 |
Accounts Payable | 4,913 | 5,356 | 5,455 | 6,807 | 4,967 |
Accrued Expenses | 1,067 | 897.02 | 901.6 | 824.11 | 734.16 |
Current Portion of Leases | 143.94 | 164.45 | 165.01 | 135.5 | 133.75 |
Current Income Taxes Payable | 370.94 | 2,161 | 267.59 | 2,105 | 486.48 |
Other Current Liabilities | 8,170 | 7,875 | 7,355 | 6,088 | 5,702 |
Total Current Liabilities | 14,665 | 16,453 | 14,145 | 15,959 | 12,023 |
Long-Term Leases | 139.26 | 268.23 | 379.12 | 3.98 | 139.48 |
Pension & Post-Retirement Benefits | 1,882 | 2,364 | 2,394 | 2,560 | 2,387 |
Other Long-Term Liabilities | 453.09 | 270.53 | 646.79 | 1,031 | 1,228 |
Total Liabilities | 17,139 | 19,356 | 17,565 | 19,554 | 15,777 |
Common Stock | 5,993 | 5,993 | 5,993 | 5,771 | 5,609 |
Additional Paid-In Capital | 1,170 | 1,170 | 1,170 | 1,170 | 1,170 |
Retained Earnings | 146,269 | 140,444 | 128,688 | 117,118 | 106,663 |
Treasury Stock | -1,358 | -1,358 | -1,358 | -1,285 | -1,180 |
Comprehensive Income & Other | 275 | 256.8 | 402.29 | 503.25 | 934.27 |
Shareholders' Equity | 152,350 | 146,506 | 134,895 | 123,277 | 113,196 |
Total Liabilities & Equity | 169,489 | 165,861 | 152,460 | 142,832 | 128,974 |
Total Debt | 283.19 | 432.68 | 544.13 | 139.48 | 273.22 |
Net Cash (Debt) | 38,931 | 33,281 | 22,875 | 23,214 | 20,597 |
Net Cash Growth | 16.98% | 45.49% | -1.46% | 12.71% | 45.04% |
Net Cash Per Share | - | 2879.07 | 1978.43 | 2086.88 | 1832.18 |
Filing Date Shares Outstanding | - | 11.56 | 11.56 | 11.12 | 11.24 |
Total Common Shares Outstanding | - | 11.56 | 11.56 | 11.12 | 11.24 |
Working Capital | 67,890 | 60,996 | 54,643 | 51,321 | 46,403 |
Book Value Per Share | - | 12673.99 | 11669.56 | 11082.32 | 10069.36 |
Tangible Book Value | 149,968 | 144,769 | 133,085 | 121,407 | 111,395 |
Tangible Book Value Per Share | - | 12523.79 | 11512.97 | 10914.20 | 9909.14 |
Land | 2,094 | 2,094 | 2,094 | 2,094 | 2,094 |
Buildings | 38,239 | 36,456 | 34,193 | 28,429 | 19,865 |
Machinery | 54,547 | 50,582 | 47,680 | 17,654 | 6,877 |
Construction In Progress | 167.4 | 3,056 | 125 | 4,994 | 1,463 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.